Literature DB >> 8475918

Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes.

J I Dickstein1, J W Vardiman.   

Abstract

We have attempted to discuss some of the issues that interest pathologists who are involved in the diagnosis of CMPD and MDS. In most cases, correlation of the clinical findings with the findings in the blood and marrow will allow the morphologist to arrive at a proper diagnosis. Nevertheless, there will continue to be cases that are difficult to classify, or in which the clinical features are out of keeping with the morphologic features. These cases are challenging and thought-provoking, and the application of newer diagnostic techniques, such as molecular genetics, may provide important insights.

Entities:  

Mesh:

Year:  1993        PMID: 8475918     DOI: 10.1093/ajcp/99.4.513

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 2.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 3.  The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002).

Authors:  John M Bennett; Peter A Kouides; Stephen J Forman
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 4.  Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 5.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.